Nonin Medical Inc., the inventor of finger pulse oximetry and a leader in noninvasive medical monitoring, announced that the U.S. Food and Drug Administration (FDA) has cleared the Nonin Model 3230 Bluetooth Smart finger pulse oximeter for use in the United States.
Biotronik Japan announced enrollment of the first patient in the Bioflow-IV study, which aims to verify the efficacy and safety of the Orsiro Hybrid Drug-Eluting Stent (DES) from Biotronik.
The American Society of Echocardiography (ASE) Foundation is announced the Echo AUC, a new mobile application that is designed to guide physicians in appropriate procedures in cardiovascular care and echocardiography, is available for download in both the Apple and Droid application stores.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Alivecor Inc. announced that the AliveCor Heart Monitor is now being offered to participants in the Health eHeart Study with 2,000 units to be deployed before the end of the year.
Researchers at The University of Texas Health Science Center at Houston (UTHealth) led a study that showed that a hands-free ultrasound device, combined with a clot-busting drug, was safe for ischemic stroke patients.
Biosensors International’s expanded product portfolio offers physicians a broader range of treatment options to improve patient outcomes.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Simbionix, a provider of innovative training solutions, announced the initiation of the REHEARSAAAL study which evaluates the clinical benefits of preoperative patient specific simulation using the PROcedure Rehearsal Studio for the treatment of Abdominal Aortic Aneurysms (AAAs) by Endovascular Aortic Repair (EVAR). A multidisciplinary group of physicians from vascular surgery, interventional radiology and cardiology departments in hospitals across the United States and Europe will conduct the study.
CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education and advancement of medical technologies, will present data from the podium at the Transcatheter Cardiovascular Therapeutics annual scientific meeting (TCT 2013) that provides a seminal experimental and computational template for a more rational, comprehensive preclinical evaluation and optimization of renal denervation devices.
A new valve recently approved by the U.S. Food and Drug Administration (FDA) now gives heart patients a new way to manage their disease without having to undergo open heart surgery.?
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
This animation, provided by Abbott Vascular, demonstrates how the U.S. Food and Drug Administration (FDA)-cleared ...
The Cardiovascular Research Foundation (CRF) announced the appointment of John (Jack) Lewin, M.D., as the foundation’s president and CEO.
The global sales of drug-eluting balloons (DEBs) across the 10 major markets (10MM) are expected to witness a significant increase over the coming years, from $164m in 2012 to $477m in 2019, at a Compound Annual Growth Rate (CAGR) of 16 percent, following the product’s launch in the United States and Japanese markets, according to a new report from research and consulting firm GlobalData.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Fluke Biomedical, a provider of medical device test and safety equipment, announced the debut of its new ProSim 2 and ProSim 3 Vital Signs Simulators. Designed for high portability, the lightweight ProSim 2 and 3 are suitable for conducting preventive maintenance and repairs in the field.
Kona Medical Inc. announced it has closed a Series D equity financing of $10 million. Morningside Group, a broad-based investment firm with significant presence in China, led the investment and is the sole investor.
Colibri Heart Valve LLC, a medical device company, announced that patient enrollment has concluded in the first-in-human study of the company's transcatheter aortic valve implantation (TAVI) system in the Dominican Republic trial site.